- Home
- DMO vs RVPHW Comparison
DMO vs RVPHW Comparison
Compare DMO & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMO
- RVPHW
- Stock Information
- Founded
- DMO 2009
- RVPHW N/A
- Country
- DMO United States
- RVPHW United States
- Employees
- DMO N/A
- RVPHW 15
- Industry
- DMO Trusts Except Educational Religious and Charitable
- RVPHW Biotechnology: Pharmaceutical Preparations
- Sector
- DMO Finance
- RVPHW Health Care
- Exchange
- DMO Nasdaq
- RVPHW Nasdaq
- Market Cap
- DMO N/A
- RVPHW N/A
- IPO Year
- DMO N/A
- RVPHW 2018
- Fundamental
- Price
- DMO $12.10
- RVPHW $0.17
- Analyst Decision
- DMO
- RVPHW
- Analyst Count
- DMO 0
- RVPHW 0
- Target Price
- DMO N/A
- RVPHW N/A
- AVG Volume (30 Days)
- DMO 49.6K
- RVPHW N/A
- Earning Date
- DMO 01-01-0001
- RVPHW N/A
- Dividend Yield
- DMO 12.06%
- RVPHW N/A
- EPS Growth
- DMO N/A
- RVPHW N/A
- EPS
- DMO N/A
- RVPHW N/A
- Revenue
- DMO N/A
- RVPHW N/A
- Revenue This Year
- DMO N/A
- RVPHW N/A
- Revenue Next Year
- DMO N/A
- RVPHW N/A
- P/E Ratio
- DMO N/A
- RVPHW N/A
- Revenue Growth
- DMO N/A
- RVPHW N/A
- 52 Week Low
- DMO $10.00
- RVPHW N/A
- 52 Week High
- DMO $11.80
- RVPHW N/A
- Technical
- Relative Strength Index (RSI)
- DMO 50.87
- RVPHW N/A
- Support Level
- DMO $11.91
- RVPHW N/A
- Resistance Level
- DMO $12.32
- RVPHW N/A
- Average True Range (ATR)
- DMO 0.13
- RVPHW 0.00
- MACD
- DMO -0.01
- RVPHW 0.00
- Stochastic Oscillator
- DMO 46.34
- RVPHW 0.00
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.